Protalix BioTherapeutics Inc. (DE) (PLX)
NYSE: PLXHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
PLX stock chart
Technical analysisKey statistics
All statistics- Market cap
- $244.52M
- P/E (TTM)
- 12.08
- Forward P/E
- 4.68
- EPS (TTM)
- $0.24
- Dividend yield
- None
- 52-week range
- 1.65 – 3.19
- Day range
- 2.87 – 3.04
- Volume / Avg
- 1.23M / 903.48K
- Beta
- —
- Shares outstanding
- 84.32M
52-week range
PLX stock today
Protalix BioTherapeutics (DE) (PLX) closed at $2.90 on Nov 20, down 5.23% (-$0.16), versus the S&P 500's 3.70% decline. At this level, PLX sits near the top of its 52-week range of $1.65 to $3.19: 9.1% below the high, set on Feb 23, 2026 and 75.8% above the low. PLX is up 61.1% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 65.7%.
Protalix BioTherapeutics (DE) trades at 12.1x its trailing twelve-month earnings per share of $0.24. Its forward P/E of 4.7x is lower than the trailing multiple, which means analysts expect earnings to rise over the next year.
Summary generated from market data by MetaCap's automated system. Methodology
About Protalix BioTherapeutics (DE)
Company profileProtalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company provides Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell expressed recombinant PEGylated Uricase, which is in Phase 2 trial for the treatment of gout; and PRX-119, a plant cell expressed PEGylated recombinant human DNase I product candidate for the treatment of neutrophil extracellular traps diseases.
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- CEO
- Mr. Dror Bashan
- Headquarters
- Hackensack, NJ
- Employees
- 226
- Website
- protalix.com
Financial highlights
Full financialsIn fiscal 2025, Protalix BioTherapeutics (DE) generated $52.7 million in revenue, down 1.2% from fiscal 2024, its first annual decline since 2024. Protalix BioTherapeutics (DE) reported a net loss of $6.6 million, compared with net income of $2.9 million a year earlier. Gross margin was 48.8% (down from 54.5%) and operating margin -10.4%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $52.74M | $53.40M | $65.49M | $47.64M | $38.35M |
| Growth | -1.23% | -18.47% | +37.48% | +24.22% | -39.03% |
| Net income | $-6.60M | $2.93M | $8.31M | $-14.93M | $-27.58M |
| EPS (diluted) | $-0.08 | $0.04 | $0.09 | $-0.31 | $-0.62 |
Analyst forecast
ForecastConsensus (1 analysts)
strong_buy
Avg. price target
$12.00+313.79%
- Strong buy 0
- Buy 1
- Hold 0
- Sell 0
- Strong sell 0
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 10, 2026
- EPS actual vs est.
- $0.05 vs $-0.02
- Surprise
- +350.00%
PLX news
All PLX news- Protalix BioTherapeutics Inc. Q3 Income AdvancesNasdaq
- Pluxee convenes its Fiscal 2026 Annual General Meeting of ShareholdersGlobeNewswire
- Pluxee convoque son Assemblée générale annuelle d’actionnaires pour l’exercice 2026GlobeNewswire
- Protalix BioTherapeutics to Announce Third Quarter 2026 Financial Results and Business Update on November 10, 2026PR Newswire
- Pluxee delivered above all Fiscal 2026 financial objectives and is gearing up for its next phase of profitable growthGlobeNewswire
- Pluxee dépasse l'ensemble de ses objectifs financiers pour l’exercice 2026 et se prépare activement à une nouvelle phase de croissance rentableGlobeNewswire
Protalix BioTherapeutics (DE) peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| LXEOLexeo Therapeutics Inc. | 2.96 | +0.34% | $245.05M | vs PLX |
| AUTLAutolus Therapeutics plc ADR | 0.9073 | -7.38% | $241.65M | vs PLX |
| EDITEditas Medicine Inc. | 1.64 | -4.09% | $253.12M | vs PLX |
| SABSSAB Biotherapeutics Inc. | 2.81 | -3.44% | $253.15M | vs PLX |
| EIKNEikon Therapeutics Inc. | 4.74 | -0.42% | $256.84M | vs PLX |
| SCTXScribe Therapeutics Inc. | 12.07 | -8.70% | $228.58M | vs PLX |
| OCGNOcugen Inc. | 0.7679 | +4.79% | $260.55M | vs PLX |
| AGMBAgomAb Therapeutics NV ADR | 5.45 | -3.02% | $268.40M | vs PLX |
Indexes, lists and sector
Protalix BioTherapeutics (DE) stock FAQ
What is Protalix BioTherapeutics (DE)'s stock price today?
PLX last traded at $2.90 as of Nov 20, 4:00 PM EST, down 5.23% on the day. Prices are delayed at least 15 minutes.
Does Protalix BioTherapeutics (DE) pay a dividend?
No. Protalix BioTherapeutics (DE) does not currently pay a regular cash dividend.
What is PLX's P/E ratio?
PLX trades at a trailing P/E ratio of 12.08 and a forward P/E of 4.68.
Who is Protalix BioTherapeutics (DE)'s CEO?
Mr. Dror Bashan is the chief executive officer of Protalix BioTherapeutics Inc. (DE), which has about 226 employees.
Has PLX ever split its stock?
Yes. The most recent PLX stock split was a 1-for-10 split on Dec 20, 2019, one of 2 splits on record.
What is the PLX 52-week high?
The 52-week high for PLX is $3.19 and the 52-week low is $1.65. The stock is currently 9.1% below its high.